Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 262

1.

Glioblastoma-Derived IL6 Induces Immunosuppressive Peripheral Myeloid Cell PD-L1 and Promotes Tumor Growth.

Lamano JB, Lamano JB, Li YD, DiDomenico JD, Choy W, Veliceasa D, Oyon DE, Fakurnejad S, Ampie L, Kesavabhotla K, Kaur R, Kaur G, Biyashev D, Unruh DJ, Horbinski CM, James CD, Parsa AT, Bloch O.

Clin Cancer Res. 2019 Jun 15;25(12):3643-3657. doi: 10.1158/1078-0432.CCR-18-2402. Epub 2019 Mar 1.

PMID:
30824583
2.

In Reply: Factors Predicting Recurrence After Resection of Clival Chordoma Using Variable Surgical Approaches and Radiation Modalities.

Jahangiri A, Chin AT, Wagner JR, Kunwar S, Ames C, Chou D, Barani I, Parsa AT, McDermott MW, Benet A, El-Sayed IH, Aghi MK.

Neurosurgery. 2017 Aug 1;81(2):E32. doi: 10.1093/neuros/nyx137. No abstract available.

PMID:
28379552
3.

Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.

Bloch O, Lim M, Sughrue ME, Komotar RJ, Abrahams JM, O'Rourke DM, D'Ambrosio A, Bruce JN, Parsa AT.

Clin Cancer Res. 2017 Jul 15;23(14):3575-3584. doi: 10.1158/1078-0432.CCR-16-1369. Epub 2017 Feb 13.

4.

Safety and outcomes of preoperative embolization of intracranial hemangioblastomas: A systematic review.

Ampie L, Choy W, Lamano JB, Kesavabhotla K, Kaur R, Parsa AT, Bloch O.

Clin Neurol Neurosurg. 2016 Nov;150:143-151. doi: 10.1016/j.clineuro.2016.09.008. Epub 2016 Sep 19. Review.

PMID:
27668858
5.

Pleomorphic Xanthoastrocytoma with Anaplastic Features: Retrospective Case Series.

Rutkowski MJ, Oh T, Niflioglu GG, Safaee M, Tihan T, Parsa AT.

World Neurosurg. 2016 Nov;95:368-374. doi: 10.1016/j.wneu.2016.07.068. Epub 2016 Jul 28.

PMID:
27476694
6.

The limited capacity of malignant glioma-derived exosomes to suppress peripheral immune effectors.

Iorgulescu JB, Ivan ME, Safaee M, Parsa AT.

J Neuroimmunol. 2016 Jan 15;290:103-8. doi: 10.1016/j.jneuroim.2015.11.025. Epub 2015 Nov 28.

PMID:
26711578
7.

Immunomonitoring in glioma immunotherapy: current status and future perspectives.

Lamano JB, Ampie L, Choy W, Kesavabhotla K, DiDomenico JD, Oyon DE, Parsa AT, Bloch O.

J Neurooncol. 2016 Mar;127(1):1-13. doi: 10.1007/s11060-015-2018-4. Epub 2015 Dec 5. Review.

8.

Role of preoperative embolization for intradural spinal hemangioblastomas.

Ampie L, Choy W, Khanna R, Smith ZA, Dahdaleh NS, Parsa AT, Bloch O.

J Clin Neurosci. 2016 Feb;24:83-7. doi: 10.1016/j.jocn.2015.09.006. Epub 2015 Nov 12.

PMID:
26585384
9.

Erratum to: Predictors of recurrence in the management of chordoid meningioma.

Choy W, Ampie L, Lamano JB, Kesavabhotla K, Mao Q, Parsa AT, Bloch O.

J Neurooncol. 2016 Jan;126(1):117. doi: 10.1007/s11060-015-1963-2. No abstract available.

PMID:
26493739
10.

Predictors of recurrence in the management of chordoid meningioma.

Choy W, Ampie L, Lamano JB, Kesavabhotla K, Mao Q, Parsa AT, Bloch O.

J Neurooncol. 2016 Jan;126(1):107-116. doi: 10.1007/s11060-015-1940-9. Epub 2015 Sep 26. Review. Erratum in: J Neurooncol. 2015 Oct 22;:.

11.

Prognostic factors for recurrence and complications in the surgical management of primary chordoid gliomas: A systematic review of literature.

Ampie L, Choy W, Lamano JB, Kesavabhotla K, Mao Q, Parsa AT, Bloch O.

Clin Neurol Neurosurg. 2015 Nov;138:129-36. doi: 10.1016/j.clineuro.2015.08.011. Epub 2015 Aug 19. Review.

12.

The kynurenine to tryptophan ratio as a prognostic tool for glioblastoma patients enrolling in immunotherapy.

Zhai L, Dey M, Lauing KL, Gritsina G, Kaur R, Lukas RV, Nicholas MK, Rademaker AW, Dostal CR, McCusker RH, Raizer JJ, Parsa AT, Bloch O, Wainwright DA.

J Clin Neurosci. 2015 Dec;22(12):1964-8. doi: 10.1016/j.jocn.2015.06.018. Epub 2015 Aug 14.

13.

Association of tumor location, extent of resection, and neurofibromatosis status with clinical outcomes for 221 spinal nerve sheath tumors.

Safaee M, Parsa AT, Barbaro NM, Chou D, Mummaneni PV, Weinstein PR, Tihan T, Ames CP.

Neurosurg Focus. 2015 Aug;39(2):E5. doi: 10.3171/2015.5.FOCUS15183.

PMID:
26235022
14.

Surgery is cost-effective treatment for young patients with vestibular schwannomas: decision tree modeling of surgery, radiation, and observation.

Zygourakis CC, Oh T, Sun MZ, Barani I, Kahn JG, Parsa AT.

Neurosurg Focus. 2014 Nov;37(5):E8. doi: 10.3171/2014.8.FOCUS14435.

PMID:
26218621
15.

Heat shock protein vaccines against glioblastoma: from bench to bedside.

Ampie L, Choy W, Lamano JB, Fakurnejad S, Bloch O, Parsa AT.

J Neurooncol. 2015 Jul;123(3):441-8. doi: 10.1007/s11060-015-1837-7. Epub 2015 Jun 21. Review.

16.

Quality improvement in neurosurgery.

Rolston JD, Han SJ, Parsa AT.

Neurosurg Clin N Am. 2015 Apr;26(2):xiii-xiv. doi: 10.1016/j.nec.2015.01.001. Epub 2015 Feb 7. No abstract available.

PMID:
25771287
17.

Survival impact of time to initiation of chemoradiotherapy after resection of newly diagnosed glioblastoma.

Sun MZ, Oh T, Ivan ME, Clark AJ, Safaee M, Sayegh ET, Kaur G, Parsa AT, Bloch O.

J Neurosurg. 2015 May;122(5):1144-50. doi: 10.3171/2014.9.JNS14193. Epub 2015 Mar 13.

PMID:
25768833
18.

Proportional upregulation of CD97 isoforms in glioblastoma and glioblastoma-derived brain tumor initiating cells.

Safaee M, Fakurnejad S, Bloch O, Clark AJ, Ivan ME, Sun MZ, Oh T, Phillips JJ, Parsa AT.

PLoS One. 2015 Feb 25;10(2):e0111532. doi: 10.1371/journal.pone.0111532. eCollection 2015.

19.

Impact of resident involvement in neurosurgery: an analysis of 8748 patients from the 2011 American College of Surgeons National Surgical Quality Improvement Program database.

Lim S, Parsa AT, Kim BD, Rosenow JM, Kim JY.

J Neurosurg. 2015 Apr;122(4):962-70. doi: 10.3171/2014.11.JNS1494. Epub 2015 Jan 23.

PMID:
25614947
20.

Factors predicting recurrence after resection of clival chordoma using variable surgical approaches and radiation modalities.

Jahangiri A, Chin AT, Wagner JR, Kunwar S, Ames C, Chou D, Barani I, Parsa AT, McDermott MW, Benet A, El-Sayed IH, Aghi MK.

Neurosurgery. 2015 Feb;76(2):179-85; discussion 185-6. doi: 10.1227/NEU.0000000000000611.

PMID:
25594191
21.

Protein kinase A-dependent phosphorylation of Dock180 at serine residue 1250 is important for glioma growth and invasion stimulated by platelet derived-growth factor receptor α.

Feng H, Li Y, Yin Y, Zhang W, Hou Y, Zhang L, Li Z, Xie B, Gao WQ, Sarkaria JN, Raizer JJ, James CD, Parsa AT, Hu B, Cheng SY.

Neuro Oncol. 2015 Jun;17(6):832-42. doi: 10.1093/neuonc/nou323. Epub 2014 Dec 2.

22.

Stable luciferase expression does not alter immunologic or in vivo growth properties of GL261 murine glioma cells.

Clark AJ, Safaee M, Oh T, Ivan ME, Parimi V, Hashizume R, Ozawa T, James CD, Bloch O, Parsa AT.

J Transl Med. 2014 Dec 3;12:345. doi: 10.1186/s12967-014-0345-4.

23.

Risk factors for postoperative cerebrospinal fluid leak and meningitis after expanded endoscopic endonasal surgery.

Ivan ME, Iorgulescu JB, El-Sayed I, McDermott MW, Parsa AT, Pletcher SD, Jahangiri A, Wagner J, Aghi MK.

J Clin Neurosci. 2015 Jan;22(1):48-54. doi: 10.1016/j.jocn.2014.08.009. Epub 2014 Nov 22. Review.

PMID:
25439754
24.

Vaccine therapies in malignant glioma.

Oh T, Sayegh ET, Fakurnejad S, Oyon D, Lamano JB, DiDomenico JD, Bloch O, Parsa AT.

Curr Neurol Neurosci Rep. 2015 Jan;15(1):508. doi: 10.1007/s11910-014-0508-y. Review.

25.

Medical errors in neurosurgery.

Rolston JD, Zygourakis CC, Han SJ, Lau CY, Berger MS, Parsa AT.

Surg Neurol Int. 2014 Oct 13;5(Suppl 10):S435-40. doi: 10.4103/2152-7806.142777. eCollection 2014.

26.

NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification.

Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD.

Mol Cancer Ther. 2014 Dec;13(12):2919-29. doi: 10.1158/1535-7163.MCT-14-0306. Epub 2014 Oct 13.

27.

Towards a hypermodern theory of meningioma surgery.

Sughrue ME, Sayegh ET, Parsa AT.

Clin Neurol Neurosurg. 2014 Nov;126:69-75. doi: 10.1016/j.clineuro.2014.06.002. Epub 2014 Jun 13.

PMID:
25215444
28.

Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas.

Ivan ME, Safaee M, Oh T, Clark AJ, Sun MZ, Kim J, Bloch O, Jahangiri A, Phillips JJ, Aghi MK, Parsa AT.

J Neurooncol. 2015 Jan;121(1):53-61. doi: 10.1007/s11060-014-1606-z. Epub 2014 Sep 9.

29.

PI3K pathway inhibitors: potential prospects as adjuncts to vaccine immunotherapy for glioblastoma.

Oh T, Ivan ME, Sun MZ, Safaee M, Fakurnejad S, Clark AJ, Sayegh ET, Bloch O, Parsa AT.

Immunotherapy. 2014;6(6):737-53. doi: 10.2217/imt.14.35. Review.

30.

Principles of surgery for malignant astrocytomas.

Sayegh ET, Oh T, Fakurnejad S, Oyon DE, Bloch O, Parsa AT.

Semin Oncol. 2014 Aug;41(4):523-531. doi: 10.1053/j.seminoncol.2014.06.011. Epub 2014 Jun 30. Review.

PMID:
25173144
31.

Anticonvulsant prophylaxis for brain tumor surgery: determining the current best available evidence.

Sayegh ET, Fakurnejad S, Oh T, Bloch O, Parsa AT.

J Neurosurg. 2014 Nov;121(5):1139-47. doi: 10.3171/2014.7.JNS132829. Epub 2014 Aug 29. Review.

PMID:
25170671
32.

Vaccine therapies for patients with glioblastoma.

Sayegh ET, Oh T, Fakurnejad S, Bloch O, Parsa AT.

J Neurooncol. 2014 Sep;119(3):531-46. doi: 10.1007/s11060-014-1502-6. Epub 2014 Aug 28. Review.

PMID:
25163836
33.

Tumor-to-tumor metastasis: breast carcinoma to meningioma.

Sayegh ET, Burch EA, Henderson GA, Oh T, Bloch O, Parsa AT.

J Clin Neurosci. 2015 Feb;22(2):268-74. doi: 10.1016/j.jocn.2014.07.002. Epub 2014 Aug 21. Review.

PMID:
25150768
34.

Management of central nervous system teratoma.

Zygourakis CC, Davis JL, Kaur G, Ames CP, Gupta N, Auguste KI, Parsa AT.

J Clin Neurosci. 2015 Jan;22(1):98-104. doi: 10.1016/j.jocn.2014.03.039. Epub 2014 Aug 21.

35.

Immune evasion mediated by tumor-derived lactate dehydrogenase induction of NKG2D ligands on myeloid cells in glioblastoma patients.

Crane CA, Austgen K, Haberthur K, Hofmann C, Moyes KW, Avanesyan L, Fong L, Campbell MJ, Cooper S, Oakes SA, Parsa AT, Lanier LL.

Proc Natl Acad Sci U S A. 2014 Sep 2;111(35):12823-8. doi: 10.1073/pnas.1413933111. Epub 2014 Aug 18.

36.

Management of planum/olfactory meningiomas: predicting symptoms and postoperative complications.

Zygourakis CC, Sughrue ME, Benet A, Parsa AT, Berger MS, McDermott MW.

World Neurosurg. 2014 Dec;82(6):1216-23. doi: 10.1016/j.wneu.2014.08.007. Epub 2014 Aug 7.

PMID:
25108294
37.

Effects of adjuvant chemotherapy and radiation on overall survival in children with choroid plexus carcinoma.

Sun MZ, Ivan ME, Oh MC, Delance AR, Clark AJ, Safaee M, Oh T, Kaur G, Molinaro A, Gupta N, Parsa AT.

J Neurooncol. 2014 Nov;120(2):353-60. doi: 10.1007/s11060-014-1559-2. Epub 2014 Aug 9.

38.

What clinical factors predict the incidence of deep venous thrombosis and pulmonary embolism in neurosurgical patients?

Rolston JD, Han SJ, Bloch O, Parsa AT.

J Neurosurg. 2014 Oct;121(4):908-18. doi: 10.3171/2014.6.JNS131419. Epub 2014 Aug 1.

PMID:
25084467
39.

EGFR phosphorylation of DCBLD2 recruits TRAF6 and stimulates AKT-promoted tumorigenesis.

Feng H, Lopez GY, Kim CK, Alvarez A, Duncan CG, Nishikawa R, Nagane M, Su AJ, Auron PE, Hedberg ML, Wang L, Raizer JJ, Kessler JA, Parsa AT, Gao WQ, Kim SH, Minata M, Nakano I, Grandis JR, McLendon RE, Bigner DD, Lin HK, Furnari FB, Cavenee WK, Hu B, Yan H, Cheng SY.

J Clin Invest. 2014 Sep;124(9):3741-56. doi: 10.1172/JCI73093. Epub 2014 Jul 25.

40.

Survival outcomes of giant cell glioblastoma: institutional experience in the management of 20 patients.

Oh T, Rutkowski MJ, Safaee M, Sun MZ, Sayegh ET, Bloch O, Tihan T, Parsa AT.

J Clin Neurosci. 2014 Dec;21(12):2129-34. doi: 10.1016/j.jocn.2014.04.011. Epub 2014 Jul 16.

PMID:
25037316
41.

Prognosis by tumor location in adults with intracranial ependymomas.

Sayegh ET, Aranda D, Kim JM, Oh T, Parsa AT, Oh MC.

J Clin Neurosci. 2014 Dec;21(12):2096-101. doi: 10.1016/j.jocn.2014.05.011. Epub 2014 Jul 15. Review.

42.

Intrameningioma metastasis of breast carcinoma.

Sayegh ET, Henderson GA, Burch EA, Reis GF, Cha S, Oh T, Bloch O, Parsa AT.

Rare Tumors. 2014 Jun 3;6(2):5313. doi: 10.4081/rt.2014.5313. eCollection 2014 May 13.

43.

Pleomorphic xanthoastrocytomas: institutional experience of 18 patients.

Oh T, Kaur G, Madden M, Bloch O, Parsa AT.

J Clin Neurosci. 2014 Oct;21(10):1767-72. doi: 10.1016/j.jocn.2014.04.002. Epub 2014 Jun 17.

PMID:
24950906
44.

Modern treatment of 84 newly diagnosed craniopharyngiomas.

Zygourakis CC, Kaur G, Kunwar S, McDermott MW, Madden M, Oh T, Parsa AT.

J Clin Neurosci. 2014 Sep;21(9):1558-66. doi: 10.1016/j.jocn.2014.03.005. Epub 2014 Jun 6.

PMID:
24908374
45.

Immunocompetent murine models for the study of glioblastoma immunotherapy.

Oh T, Fakurnejad S, Sayegh ET, Clark AJ, Ivan ME, Sun MZ, Safaee M, Bloch O, James CD, Parsa AT.

J Transl Med. 2014 Apr 29;12:107. doi: 10.1186/1479-5876-12-107. Review.

46.

Facial neuroma masquerading as acoustic neuroma.

Sayegh ET, Kaur G, Ivan ME, Bloch O, Cheung SW, Parsa AT.

J Clin Neurosci. 2014 Oct;21(10):1817-8. doi: 10.1016/j.jocn.2013.12.029. Epub 2014 Apr 26.

PMID:
24775608
47.

Pigmented villonodular synovitis of the temporomandibular joint with intracranial extension: A case series and systematic review.

Safaee M, Oh T, Sun MZ, Parsa AT, McDermott MW, El-Sayed IH, Bloch O.

Head Neck. 2015 Aug;37(8):1213-24. doi: 10.1002/hed.23717. Epub 2014 Jul 11. Review.

PMID:
24764167
48.

Heat shock protein peptide complex-96 (HSPPC-96) vaccination for recurrent glioblastoma: a phase II, single arm trial.

Bloch O, Parsa AT.

Neuro Oncol. 2014 May;16(5):758-9. doi: 10.1093/neuonc/nou054. Epub 2014 Apr 10. No abstract available.

49.

Complement anaphylatoxins as immune regulators in cancer.

Sayegh ET, Bloch O, Parsa AT.

Cancer Med. 2014 Aug;3(4):747-58. doi: 10.1002/cam4.241. Epub 2014 Apr 8. Review.

50.

Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review.

Kaur G, Sayegh ET, Larson A, Bloch O, Madden M, Sun MZ, Barani IJ, James CD, Parsa AT.

Neuro Oncol. 2014 May;16(5):628-36. doi: 10.1093/neuonc/nou025. Epub 2014 Apr 2. Review.

Supplemental Content

Loading ...
Support Center